Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06502366 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma
A Phase 3 study of Asthma, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 422
- Enrollment target
- 20
- Study locations
NCT06502366 is a Phase 3 study of Asthma that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 422 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT06502366, a Phase 3 study of Asthma, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 422 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the PD equivalence of the approved asthma combination therapy, BDA, delivered using the proposed replacement propellant HFO compared with BDA delivered using the currently approved propellant HFA in participants with asthma.
Conditions Studied
Interventions
- DRUG BDA MDI HFO 160/180 μg
- DRUG BDA MDI HFA 160/180 μg
- DRUG Placebo MDI HFA
Study Locations (20)
California
- Research Site - Encinitas
- Research Site - Fullerton
- Research Site - Gardena
- Research Site - Huntington Beach
- Research Site - La Mesa
- Research Site - Los Angeles
- Research Site - Los Angeles
- Research Site - Sacramento
- Research Site - San Bernardino
- Research Site - San Diego
- Research Site - San Jose
- Research Site - Santa Ana
- Research Site - Stockton
- Research Site - Westminster
Alabama
- Research Site - Mobile
- Research Site - Sheffield
Colorado
- Research Site - Englewood
- Research Site - Wheat Ridge
Arizona
- Research Site - Phoenix
Arkansas
- Research Site - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 422 participants |
| Start Date | 2024-07-22 |
| Est. Completion | 2026-03-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06502366
The ClinicalTrials.gov registry entry for NCT06502366 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 422 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (73% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 3 interventions - of which BDA MDI HFO 160/180 μg is the first listed.
NCT06502366 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Alabama, Colorado.
Frequently Asked Questions
What is clinical trial NCT06502366 about?
NCT06502366 is a clinical study titled "A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma". The purpose of this study is to assess the PD equivalence of the approved asthma combination therapy, BDA, delivered using the proposed replacement propellant HFO compared with BDA delivered using the currently approved propellant HFA in participants with asthma.
What is the current status of trial NCT06502366?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 422 participants. The study started on 2024-07-22. Estimated completion is 2026-03-03.
What conditions does trial NCT06502366 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT06502366?
The interventions under investigation include: BDA MDI HFO 160/180 μg (DRUG), BDA MDI HFA 160/180 μg (DRUG), Placebo MDI HFA (DRUG).
Who is sponsoring clinical trial NCT06502366?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06502366 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.